North American Nuclear Medicine Radiopharmaceuticals Market: Market Size & Forecast 2026

Nuclear medicine radiopharmaceuticals are radioactive drugs administered to patients for diagnostic imaging or targeted radiotherapy. The North American market, valued at $5.49 billion in 2025, encompasses both well-established diagnostic agents like technetium-99m and fluorodeoxyglucose (FDG), and newer therapeutic compounds using isotopes such as lutetium-177. Growth is fueled by the precision advantages these agents offer in oncology, cardiology, and neurology compared to conventional imaging modalities.

• •SPECT agents, particularly technetium-99m based products, represent the largest diagnostic segment
• •PET radiopharmaceuticals, including FDG and novel amyloid/tau tracers, command premium pricing
• •Therapeutic radiopharmaceuticals targeting neuroendocrine tumors and prostate cancer are expanding rapidly

Rising cancer incidence across North America is a primary catalyst, as nuclear medicine offers critical tools for detection, staging, and treatment. The aging baby boomer population increases demand for both diagnostic cardiac and oncologic imaging. Additionally, technological advances in hybrid imaging systems like PET/CT and SPECT/CT have improved clinical utility and adoption rates across hospital networks.

• •Approximately 1.9 million new cancer cases are projected annually in the United States, driving imaging and therapy demand
• •Medicare and private payer reimbursement expansions for novel radiopharmaceuticals support market access
• •Supply chain investments in domestic isotope production are reducing historical dependency on foreign reactors

The market spans diagnostic imaging agents and targeted radionuclide therapies, with the United States accounting for the vast majority of North American revenue. Canada maintains a smaller but sophisticated market with universal healthcare coverage supporting nuclear medicine access. Within diagnostics, SPECT imaging dominates by procedure volume, while PET tracers grow faster due to precision oncology applications.

• •Diagnostic radiopharmaceuticals comprise roughly 80-85% of the current market value
• •Theranostic pairs, combinations of diagnostic and therapeutic isotopes, represent the fastest-growing category
• •U.S. government initiatives to reshore medical isotope production are creating new regional supply chains

What are the recent trends and outlook?

The convergence of diagnostic imaging and targeted therapy, termed theranostics, is reshaping product development pipelines across the industry. Radioimmunotherapy and peptide receptor radionuclide therapy (PRRT) applications are extending beyond oncology into neurology and cardiology. Looking toward 2035, domestic isotope production initiatives and regulatory pathways for novel agents are expected to sustain the double-digit growth trajectory.

• •Lutetium-177 and actinium-225 based therapies are attracting substantial pharmaceutical investment
• •Artificial intelligence integration with PET/SPECT imaging is improving quantitative accuracy and workflow efficiency
• •Point-of-care radiopharmacy systems are enabling broader hospital access to short-lived PET isotopes